Novo Nordisk's new obesity drug Wegovy certainly seems to have gotten off to a great start in the US following its approval from the US Food and Drug Administration (FDA) in early June.
Over the course of the first five weeks, more than 8,000 prescriptions have been issued for the new obesity drug, which is based around the GLP-1 analog semaglutide. This is a significantly faster development than what Novo Nordisk's other drug Saxenda went through, which was launched in 2015. It is based on the substance liraglutide, which is a predecessor to semaglutide.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.